Comparing the current results to its competitors, Co Diagnostics Inc reported Revenue increase in the 2 quarter 2026 by 1.98 % year on year. The revenue growth was below Co Diagnostics Inc 's competitors' average revenue growth of 4.05 %, achieved in the same quarter.
Co diagnostics Inc , slower than the average decrease reported by the company's competitors of -1.6 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -1.6 %
April 12, 2024
Reflecting the biotech industry s rapid growth in Utah, Co-Diagnostics, Inc., a prominent molecular diagnostics company, has unveiled a brand new manufacturing facility in Salt Lake City. On April 12, 2024, the organization celebrated this significant milestone with a grand ribbon-cutting event. The inauguration drew the attendance of several dignitaries, including Mayor Wood of South Salt Lake.Co-Diagnostics, Inc., listed on NASDAQ as CODX, specializes in the development of molecular diagnostic tests. Their exceptional, patented platform forms the basis for their novel diagnostic tests. With this new facility, Co-Diagnostics aims to expand their production capacity, drive innovation, and serve an even wider...
Odyssey Health Inc is a healthcare organization that employs a subscription-based business model. The company provides comprehensive medical services to its members for a monthly fee, offering personalized healthcare solutions and a range of preventative care services. Through this model, Odyssey Health aims to ensure accessible and affordable healthcare for individuals and families.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Bionano Genomics Inc is a biotechnology company specializing in the development and commercialization of genomic analysis tools. Their business model revolves around offering proprietary genome imaging systems that provide high-resolution maps of DNA for researchers and clinicians to study genetic variations and diseases more effectively.
Sources:
Co diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Co diagnostics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
